IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma

Article metrics

Abstract

Background

Opsoclonus-myoclonus syndrome (OMS) is a rare neurological disorder, usually accompanied by neuroblastoma (NB). There is no targeted treatment and animal model of OMS. We aimed to investigate whether insulin-like growth factor 1 (IGF-1)/phosphoinositide 3-kinase (PI3K) signaling alleviates neuronal cytolysis in pediatric OMS.

Methods

Cultured rat cerebral cortical neurons and cerebellar neurons were incubated with sera or IgG isolated from sera of children with OMS and NB. Cytolysis and PI3K expression were measured by the lactate dehydrogenase assay and enzyme-linked immunosorbent assay, respectively. Using inhibitors and activators, the effects of IGF-1 and PI3K on cytolysis were investigated.

Results

The incubation of sera or IgG from children with OMS and NB increased cytolysis in not only cerebellar neurons, but also cerebral cortical neurons. Furthermore, the IGF-1 receptor antagonist NVP-AEW541 exaggerated cytolysis in children with OMS and NB. IGF-1 alleviated cytolysis, which was blocked by the PI3K inhibitor LY294002. Additionally, sera or IgG from children with OMS and NB compensatively elevated PI3K expression. LY294002 exacerbated cytolysis; whereas, the PI3K activator 740 Y-P suppressed cytolysis.

Conclusion

IGF-1/PI3K signaling alleviates the cytolysis of cultured neurons induced by serum IgG from children with OMS and NB, which may be innovation therapy targets.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. 1.

    Hasegawa, S. et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev. 37, 656–660 (2015).

  2. 2.

    Armangue, T. et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 73, 417–424 (2016).

  3. 3.

    Korfei, M. et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J. Neuroimmunol. 170, 150–157 (2005).

  4. 4.

    Blaes, F., Pike, M. G. & Lang, B. Autoantibodies in childhood opsoclonus-myoclonus syndrome. J. Neuroimmunol. 201, 221–226 (2008).

  5. 5.

    Fuhlhuber, V. et al. Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation. J. Neuroimmunol. 289, 182–186 (2015).

  6. 6.

    Panzer, J. A., Anand, R., Dalmau, J. & Lynch, D. R. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J. Neuroimmunol. 286, 86 (2015).

  7. 7.

    Bravo, J., Lopez-Almaraz, R., Mateos, M., Diaz, L. & Hernandez-Exposito, S. Neuropsychological profile in opsoclonus-myoclonus-ataxia syndrome presenting as neuroblastic tumours. Rev. Neurol. 62, 249–257 (2016).

  8. 8.

    Pranzatelli, M. R., Tate, E. D. & McGee, N. R. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol. 8, 468 (2017).

  9. 9.

    Oh, S. Y. et al. Longitudinal multi-modal neuroimaging in opsoclonus-myoclonus syndrome. J. Neurol. 264, 512–519 (2017).

  10. 10.

    Anand, G. et al. Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. Dev. Med. Child Neurol. 57, 265–272 (2015).

  11. 11.

    Kanjanasut, N., Phanthumchinda, K. & Bhidayasiri, R. HIV-related opsoclonus-myoclonus-ataxia syndrome: report on two cases. Clin. Neurol. Neurosurg. 112, 572–574 (2010).

  12. 12.

    Markakis, I., Alexiou, E., Xifaras, M., Gekas, G. & Rombos, A. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin. Neurol. Neurosurg. 110, 619–621 (2008).

  13. 13.

    Berridge, G. et al. Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology 91, e714–e723 (2018).

  14. 14.

    Kim, W. et al. miR-126 contributes to Parkinson’s disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol. Aging 35, 1712–1721 (2014).

  15. 15.

    Laurino, L. et al. PI3K activation by IGF-1 is essential for the regulation of membrane expansion at the nerve growth cone. J. Cell Sci. 118, 3653–3662 (2005).

  16. 16.

    Wang, Y. S. et al. IGF-1 alleviates NMDA-induced excitotoxicity in cultured hippocampal neurons against autophagy via the NR2B/PI3K-AKT-mTOR pathway. J. Cell Physiol. 229, 1618–1629 (2014).

  17. 17.

    Dai, R. Y., Chen, R. & Li, H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J. Oncol. 34, 1749–1757 (2009).

  18. 18.

    Matthay, K. K. et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 228, 275–282 (2005).

  19. 19.

    Cao, G. D. et al. Caspase-activated DNase/DNA fragmentation factor 40 mediates apoptotic DNA fragmentation in transient cerebral ischemia and in neuronal cultures. J. Neurosci. 21, 4678–4690 (2001).

  20. 20.

    Garcia-Echeverria, C. et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5, 231–239 (2004).

  21. 21.

    Williams, E. J. & Doherty, P. Evidence for and against a pivotal role of PI 3-kinase in a neuronal cell survival pathway. Mol. Cell Neurosci. 13, 272–280 (1999).

  22. 22.

    Ding, X. et al. BDNF contributes to the development of neuropathic pain by induction of spinal long-term potentiation via SHP2 associated GluN2B-containing NMDA receptors activation in rats with spinal nerve ligation. Neurobiol. Dis. 73, 428–451 (2015).

  23. 23.

    Synofzik, M. et al. Acetazolamide-responsive exercise-induced episodic ataxia associated with a novel homozygous DARS2 mutation. J. Med. Genet 48, 713–715 (2011).

  24. 24.

    Kowal, C. et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl Acad. Sci. USA 103, 19854–19859 (2006).

  25. 25.

    Bravo-Zehnder, M. et al. Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol. 67, 204–214 (2015).

  26. 26.

    Chatterjee, S. et al. Phenotypic spectrum and responses to recombinant human IGF1 (rhIGF1) therapy in patients with homozygous intronic pseudoexon growth hormone receptor mutation. Eur. J. Endocrinol. 178, 481–489 (2018).

  27. 27.

    Costales, J. & Kolevzon, A. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci. Biobehav. Rev. 63, 207–222 (2016).

  28. 28.

    Soletti, R. C. et al. Peptide gomesin triggers cell death through L-type channel calcium influx, MAPK/ERK, PKC and PI3K signaling and generation of reactive oxygen species. Chem. -Biol. Interact. 186, 135–143 (2010).

  29. 29.

    Sarro, E. et al. Phosphoinositide 3-kinase inhibitors protect mouse kidney cells from cyclosporine-induced cell death. Kidney Int. 73, 77–85 (2008).

  30. 30.

    Park, H. H. et al. L-DOPA-induced neurotoxicity is reduced by the activation of the PI3K signaling pathway. Toxicology 265, 80–86 (2009).

  31. 31.

    Xie, Z. Y. et al. Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats. Neuropharmacology 128, 142–151 (2018).

  32. 32.

    Gao, Q. G., Xie, J. X., Wong, M. S. & Chen, W. F. IGF-I receptor signaling pathway is involved in the neuroprotective effect of genistein in the neuroblastoma SK-N-SH cells. Eur. J. Pharmacol. 677, 39–46 (2012).

  33. 33.

    Yamaguchi, A. et al. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J. Biol. Chem. 276, 5256–5264 (2001).

  34. 34.

    Heck, S., Lezoualc’h, F., Engert, S. & Behl, C. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappa B. J. Biol. Chem. 274, 9828–9835 (1999).

  35. 35.

    Blaes, F. et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann. Neurol. 58, 313–317 (2005).

  36. 36.

    Werner, C. et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain 139, 365–379 (2016).

  37. 37.

    Lu, X. Y. et al. Anti-alpha-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis. PLoS ONE 5, e11124 (2010).

  38. 38.

    Gunn, A. P. et al. Amyloid-β peptide Aβ3pE-42 induces lipid peroxidation, membrane permeabilization, and calcium influx in neurons. J. Biol. Chem. 291, 6134–6145 (2016).

Download references

Funding

The present work was supported by grants from the Beijing Talents Fund (2015000021469G204) and the Basic Medicine and Clinical Medicine Cooperation Fund of Capital Medical University (15JL70, 16JL20).

Author information

Correspondence to Huan-Min Wang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark